Sir John is Chairman of the Newcastle upon Tyne Hospitals NHS Foundation Trust, Professor of Clinical Genetics at Newcastle University, led the regional NHS Genetics Service for 20 years and helped to create the International Centre for Life.

Jonathan is the co-founder of QuantuMDx, former Chief Scientific Officer and inventor of many of its proprietary technologies. Jonathan has a specialist interest in antimicrobial resistance (AMR) and was a diagnostics advisor for the O’Neill Review. He was awarded European CTO of the Year in 2015.

Elaine is the co-founder and former CEO of QuantuMDx. She is an entrepreneur with over 30 years’ healthcare and biotechnology experience. Elaine took QuantuMDx from concept to product, raising over £50m in both equity and grants. Elaine has raised over £100m in funding as an entrepreneur and was awarded an OBE for services to innovation in healthcare in 2014.

Nigel is the former CEO of Barclays Global Investors – Europe & Asia. As one of QuantuMDx’s earliest investors, Nigel has played a key role in supporting the management team in navigating the challenges of operating as a start-up.

Mirre is the Chief Executive Officer of Reggeborgh Medical and a Consultant Surgeon at Xpert Clinics, a private specialist medical service provider with 30 locations across the Netherlands. Mirre has over 20 years of experience in healthcare, strategy and innovation.

James is the managing partner and co-founder of Vita Spring IVD Fund, who participated as the institutional investor, and support the management team in fund raising and strategic development. Prior to his investment career, he worked as an investment banker for seven years and was an Executive Director in Goldman Sachs.

As one of QuantuMDx’s earliest investors, Tony has played a key role in supporting the management team, providing key strategic advice and guidance.

Martin has over 25 years’ experience of working with large global companies. He previously set up and managed Excalibur Medicines Ltd, he sits on the Board of Interrad Medical and is a Partnership Board Member of the Liverpool Life Sciences Accelerator.

Justine has been with QuantuMDx Group for almost eight years and in that time has gathered a wealth of experience of working in the life sciences sector. Justine joined as Financial Controller in 2015, and was promoted to VP Finance in 2018. In that time, Justine has developed a high-performing financial team, introduced and enhanced the managment reporting within the Company, transitioned the statutory reporting to IFRS from UK GAAP, maximised R&D tax credit subsidies to the business, managed the implementation of the ERP system and been instrumental in all of the Company's recent fund-raising activities. Justine qualified as an ACA with the "Big Four" accountancy firm, EY and left two years post-qualification. Since then, Justine has worked across financial departments in both local SMEs and large Global Companies, her most recent post prior to joining QuantuMDx was Financial Reporting Manager at FTSE 100 Company, The Sage Group plc.

Marie joined QuantuMDx as employee number 1, over 10 years ago. She is responsible for setting up and growing the operations function of the Company, with the founding team. Previously to joining QuantuMDx, Marie was in the Banking and Teaching Sectors. She has a first class degree in Accountancy and Finance Management with Mathematics and a PGCE in Mathematics both from the University of Sheffield. As VP Operations, Marie has built and manages a team executing our day to day business operations management. Marie has extensive experience of contracting, supplier engagement, contract and licence negotiation, HR, logistics and supply chain management.

Andy is a specialist in global operations and manufacturing with over 24 years' experience in the medical device and life sciences sector. During a 13-year tenure with Thermofisher, he successfully launched over 40 products in the UK and German facilities. The remaining time at Thermofisher was spent in the life sciences division leading a 24x7 manufacturing facility as site Operations Manager, with a turnover of $38M and 156 employees, outputting over 10 million PCR consumables per year. Andy led all operational activities across the site, initiated and managed the continuous improvement program, which led to his site being awarded best in class. The site expanded by 25%, establishing an ISO-13485 manufacturing facility and supplying customers such as Roche. Andy gained start-up experience with Vivacta Ltd where he was Director of Manufacturing during the lead up to the acquisition by Novartis. He then progressed to Global Head of Manufacturing Operations and during his 5-year tenure, Andy fulfilled Novartis' high standards leading and establishing in house manufacturing of Niji cassette consumables in the UK and successfully achieving ISO-13485 certification. Andy also participated in assessing potential new technology acquisitions.

Caroline has over 20 years of experience in Quality and Regulattory Affairs across multiple healthcare-related industries including Pharmaceuticals, Laboratory Testing and IVD Medical Devices, specifically Near-Patient Testing. Caroline is currently responsible for leading Quality Assurance, Quality Control, Product Risk Management and Regulatory Affairs for QuantuMDx Group and is the designated Person Responsible for Regulatory Compliance, ensuring the Company maintains an accurate view of the changing global regulatory landscape. Caroline has made successful submissions globally with approvals and registrations in UK, USA, Belgium, France, Italy, Greece and Qatar with applications underway with US FDA and SFDA. Caroline is competent with WHO PQ, WHO EUL, US EUA and MHRA derogation for emergency use pathways, has significant experience in IVDD, MDD, MDR, IVDR, GAMP5, 21CFR820 and standards including ISO 13485, ISO 14971, ISO 62366, IEC 62304, ISO 20916 and ISO 23640. Finally, Caroline is an experienced mentor and supporter of Women in Leadership Roles.

Robin is a specialist in biosensor technologies with over 18 years’ experience working in academia and industry. Robin has in-depth experience of molecular biology and surface chemistry and currently leads our project management team.

Jennie joined QuantuMDx in September 2021. Prior to joining, whe worked as a Sales Director for Oxford Immunotec, a $74 million-revenue global high growth diagnostics company from 2014-2021, leading the NW European sales teams and achieving double digit growth in a competitive specialised market, Oxford was acquired by Perkin Elmer in 2019. Prior to this, Jennie was employed in sales leadership roles and has over 30 years' experience within the pharmaceutical and diagnostic health care industry. She worked for J&J, where she headed up a team of Healthcare Development Executives, working to seek partnerships in diabetes in the primary care environment, and Roche, where she managed a team of Healthcare Managers operating across the oncology and haematology portfolio.